Description

hFSH-β-(33-53) TFA, a thiol-containing peptide which corresponds to a second FSH receptor-binding domain, is a FSHR (follicle-stimulating hormone receptor) antagonist. hFSH-β-(33-53) TFA inhibits binding of FSH to receptor and is a partial agonist of estradiol synthesis in Sertoli cells[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-programmed cell death–C115H183N31O32S.xC2HF3O2—-[1]Grasso P, et al. A synthetic peptide corresponding to hFSH-beta-(81-95) has thioredoxin-like activity. Mol Cell Endocrinol. 1991;78(3):163-170. |[2]Xu Y, et al. Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging. Mol Imaging Biol. 2014;16(4):578-585. |[3]Santa-Coloma TA, et al. Serine analogues of hFSH-beta-(33-53) and hFSH-beta-(81-95) inhibit hFSH binding to receptor. Biochem Biophys Res Commun. 1992;184(3):1273-1279. —-2543.94 (free acid)–99.81–O=C([C@H]1N(CCC1)C([C@H](CC(O)=O)NC([C@H](CCCCN)NC([C@@H](NC([C@H](C(C)C)NC([C@H](CC(C)C)NC([C@H](CC(O)=O)NC([C@H](CCCNC(N)=N)NC([C@H]([C@H](O)C)NC([C@@H](N)CC2=CC=C(C=C2)O)=O)=O)=O)=O)=O)=O)CC3=CC=C(C=C3)O)=O)=O)=O)N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N4[C@@H](CCC4)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H]([C@H](O)C)C(N[C@@H](CS)C(N[C@@H]([C@H](O)C)C(N[C@H](C(O)=O)CC5=CC=CC=C5)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O–Cancer–DMSO : 100 mg/mL (ultrasonic)–Estrogen Receptor/ERR—-Vitamin D Related/Nuclear Receptor–Peptides